Avelumab and Merkel Cell Carcinoma: Examining the Scientific Evidence

Legacy of General Health and Science Information

The Immunodeficiency Foundation has long served as a trusted repository for general health and science information, chronicling the broad evolution of immunological understanding. Its archives document foundational principles of immune system function, from basic host defense mechanisms to the historical context of therapeutic interventions. This legacy of accessible, neutral scientific reporting provides a critical backdrop for examining contemporary pharmaceutical applications and their real-world implications. Within this framework, the transition from general immunology to specific occupational exposure concerns becomes a natural progression. As therapeutic agents move from controlled clinical trials into widespread clinical use, the need arises to scrutinize their safety profiles in diverse populations, including those with occupational exposure. Avelumab, a programmed death-ligand 1 (PD-L1) blocking antibody approved for certain malignancies, represents a case where the bridge between general health information and exposure risk is particularly relevant.

Bridge to Occupational Exposure Concerns

While the foundation’s historical records emphasize immune competence and disease prevention, the modern therapeutic landscape introduces questions about unintended consequences of immune modulation. This pivot from general health context to occupational exposure concern focuses on the scientific evidence connecting Avelumab administration to subsequent Merkel cell carcinoma development, without delving into mechanistic claims. The transition thus reframes the foundation’s archival mission toward evaluating real-world pharmacovigilance data in occupational settings. Avelumab (Bavencio) is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It is approved in the United States, the European Union, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis (https://pubmed.ncbi.nlm.nih.gov/33439294/).

Scientific Evidence: Avelumab as a Therapeutic Agent

Avelumab was the first therapeutic agent specifically approved for this indication, and its approval was based on the two-part, single-arm, phase II trial JAVELIN Merkel 200, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC (https://pubmed.ncbi.nlm.nih.gov/29799096/). Merkel cell carcinoma is a rare, highly aggressive skin cancer with neuroendocrine differentiation, associated with chronic exposure to ultraviolet light and the Merkel cell polyoma virus (https://pubmed.ncbi.nlm.nih.gov/35877101/). The incidence of MCC is increasing, and the disease is associated with high rates of recurrence and mortality (https://pubmed.ncbi.nlm.nih.gov/35877101/). Immune checkpoint inhibitors, including avelumab, have significantly improved treatment outcomes in metastatic disease, with response rates to PD-1/PD-L1 inhibition of up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/). However, approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). The mechanistic pathway linking avelumab to Merkel cell carcinoma is not one of causation but of therapeutic intervention. Avelumab is used to treat MCC, not to cause it. The drug functions by blocking PD-L1, thereby enhancing the immune system's ability to recognize and attack cancer cells.

Risk Context and Immune-Related Adverse Events

Checkpoint inhibitors including avelumab are known to cause overactivation of the immune system, leading to immune-related adverse events (irAEs) (https://pubmed.ncbi.nlm.nih.gov/31543781/). For example, a case report described hypercalcemia secondary to reactivation of sarcoidosis in a patient with metastatic MCC on avelumab, which was managed with corticosteroids and allowed continuation of avelumab therapy (https://pubmed.ncbi.nlm.nih.gov/31543781/). This illustrates that while avelumab is not a cause of MCC, it can induce immune-related complications in treated patients. For patients with avelumab-refractory MCC, efficient and safe treatment options are lacking (https://pubmed.ncbi.nlm.nih.gov/33439294/). Studies have investigated the use of combined ipilimumab and nivolumab in avelumab-refractory patients. In a retrospective study at three German sites, three out of five patients with metastatic MCC refractory to avelumab responded to combined ipilimumab and nivolumab according to RECIST 1.1 criteria (https://pubmed.ncbi.nlm.nih.gov/33439294/). A multicenter study from the prospective skin cancer registry ADOREG also reported on ipilimumab plus nivolumab in avelumab-refractory MCC, noting that immune checkpoint inhibition has significantly improved treatment outcomes in metastatic disease (https://pubmed.ncbi.nlm.nih.gov/36450381/). Another retrospective study confirmed that ipilimumab plus nivolumab is used in anti-PD-L1/PD-1 refractory MCC, highlighting that despite advances, about 50% of patients progress on initial immune checkpoint inhibitor therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/).

Causation Considerations and Timeline

Regarding risk considerations, the adequacy of warnings about avelumab and MCC must be understood in context. Avelumab is approved specifically for the treatment of MCC, and its prescribing information includes warnings about immune-related adverse events, but not about causing MCC, as the drug is indicated for that disease. For affected patients, causation-related considerations focus on whether avelumab treatment is appropriate for their MCC, and whether they are at risk for immune-related adverse events. The timeline between exposure to avelumab and documented harm typically involves the development of immune-related adverse events during treatment, which can occur weeks to months after initiation. For example, the case of hypercalcemia due to sarcoidosis reactivation occurred during avelumab treatment for metastatic MCC (https://pubmed.ncbi.nlm.nih.gov/31543781/). In contrast, the timeline for avelumab-refractory disease is assessed during treatment, with progression documented at the time of radiographic or clinical evaluation. In summary, the scientific evidence establishes avelumab as a therapeutic agent for Merkel cell carcinoma, not a cause of the disease. The drug's mechanism of action involves immune checkpoint inhibition, which can lead to immune-related adverse events but does not induce MCC. For patients with avelumab-refractory MCC, alternative immune checkpoint inhibitor combinations may offer benefit, though data are limited to small retrospective studies.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

Does avelumab cause Merkel cell carcinoma?

No, avelumab is a therapeutic agent used to treat Merkel cell carcinoma (MCC), not to cause it. The drug is an immune checkpoint inhibitor that blocks PD-L1, enhancing the immune system's ability to attack cancer cells. Scientific evidence supports its use in treating MCC, and there is no evidence that avelumab causes MCC.

What are the risks associated with avelumab treatment?

Avelumab can cause immune-related adverse events (irAEs) due to overactivation of the immune system. These can include conditions like sarcoidosis reactivation, as reported in a case study (https://pubmed.ncbi.nlm.nih.gov/31543781/). Patients should be monitored for irAEs during treatment.

What treatment options exist for patients with avelumab-refractory MCC?

For patients whose MCC progresses on avelumab, alternative immune checkpoint inhibitor combinations such as ipilimumab plus nivolumab have shown benefit in small retrospective studies (https://pubmed.ncbi.nlm.nih.gov/33439294/, https://pubmed.ncbi.nlm.nih.gov/36450381/, https://pubmed.ncbi.nlm.nih.gov/35877101/). However, data are limited.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel Cell Carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.